Sutro Biopharma, Inc. STRO
15.98
0.27
1.72%
as of 25 Sep
- Market cap
- $260.5M
- P/E
- 0.0×
Follow STRO
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(1,810.01%) | 435.02% | 331.40% | 266.76% | |
| (65.54%) | (68.12%) | (54.53%) | (79.08%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(175.43%) | (221.06%) | (96.29%) | (137.78%) | |
Average Days of Receivables |
13.55 | 14.16 | 45.75 | 46.30 | |
Free Cash Flow per Share |
(26.52) | (21.06) | (11.63) | (8.79) | |
Free Cash Flow |
(225.11) | (178.93) | (152.14) | (145.62) | |
Capital Expenditures |
(2.58) | (1.69) | (0.53) | (0.45) | |
Piotroski F-Score |
0.00 | 2.00 | 4.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(277.04%) | (1,974.50%) | (111.75%) | (237.88%) | |
Accounts Receivable Turnover |
19.98 | 16.28 | 7.65 | 6.63 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.01 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
190.08% | 162.38% | 151.97% | 316.71% | |
Selling, General and Administrative Expense of Revenue |
39.18% | 40.02% | 35.47% | 71.81% | |
Share Based Compensation of Revenue |
17.29% | 13.67% | 10.07% | 14.83% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.03 | 0.93 | 0.99 | 0.80 | |
Depreciation/Fixed assets |
0.23 | 0.37 | 0.42 | 0.46 | |
Capex/Depreciation |
(0.83) | (0.44) | (0.14) | (0.11) | |
Revenue per Share |
12.45 | 12.06 | 7.61 | 2.76 | |
Operating CF per Share |
(26.22) | (20.86) | (11.59) | (8.76) | |
Capex per Share |
(0.30) | (0.20) | (0.04) | (0.03) | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.01 | |
Net Profit Margin |
(205.18%) | (186.45%) | (154.21%) | (395.25%) |
Columns are period end dates